pemetrexed,cisplatin,gemcitabine,pembrolizumab
merck
['kn-671', 'nsclc', 'sclc']
kn-671 confirming superiority of perioperative chemo+io over chemo in early stage nsclc. 2 year efs 62.4% vs 40.6% &amp; mpr 30.2% vs 11% both strongly stat significant. major question remains unanswered: added value of adjuvant io? #asco2023 
MD MSc  - Thoracic Oncology, master in hospital and health care management Hasselt - Belgium 🇧🇪 - PhD candidate Amsterdam/Leiden - he/him 🌈